TBI-223

TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb) . TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis[1][2].

Product Specifications

CAS Number

[2071265-08-0]

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/tbi-223.html

Purity

99.73

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(OC)NC[C@H]1CN(C2=CC=C(N(C3)CC43COC4)C(F)=C2)C(O1)=O

Molecular Formula

C17H20FN3O5

Molecular Weight

365.36

References & Citations

[1]Negatu DA, et al. Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. Antimicrob Agents Chemother. 2023 Apr 18;67 (4) :e0165522. |[2]Gordon O, et al. The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection. Microbiol Spectr. 2022 Oct 26;10 (5) :e0245121.